Keywords: Eli Lilly, Cialis, Erectile dysfunction and BHP, Ph III, prosatic hyperplasia

Lilly’s Cialis meets endpoints in Ph III study in men with both erectile dysfunction and BPH

Article | 13 October 2011

Print This

US drug major Eli Lilly (NYSE: LLY) says that a pivotal Phase III study of its blockbuster erectile dysfunction drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in